Increased Cytotoxicity Against B-Chronic Lymphocytic Leukemia by Cellular Manipulations: Potentials for Therapeutic Use

References

• Caligaris-Cappio E., Hamblin T. J. B-Cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather. Journal of Clinical Oncology 1999; 17: 399–408
   PubMed Web of Science ®Google Scholar
• Jewell A. P., Worman C. P., Giles F. J., Goldstone A. H., Lydyard P. M. Resistance of Chronic Lymphocytic Leukaemia Cells to Interferon-α Generated Lymphokine Activated Killer Cells. Leukemia and Lymphoma 1992; 7: 473–480
   PubMed Web of Science ®Google Scholar
• Kipps T. J. Immunoglobulin genes in chronic lymphocytic leukemia. Blood Cells 1998; 19: 615–625
   Google Scholar
• Cordone I., Masi S., Mauro F R., Soddu S., Morsillo O., Valentini T., Vegna M. L., Guglielmi C., Maneini F., Giuliacci S., Sacchi A., Mandelli F., Foa R. p53 Expression in B-Cell Chronic Lymphocytic Leukemia: A Marker of Disease Progression and Poor Prognosis. Blood 1998; 91: 4342–4349
   PubMed Web of Science ®Google Scholar
• Panayiotidis P., Kotsi P. Genetics of small lymphocyte disorders. Semin Hematol. 1999; 36: 171–177
   PubMed Web of Science ®Google Scholar
• Pavletic Z. S., Bierman P. J., Vose J. M., Bishop M. R., Wu C. D., Pierson J. L., Kollath J. P., Weisenburger D. D., Kessinger A., Armitage J. O. High incidence of relapse after autologous stem-cell transplantation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma. Annals of Oncology 1998; 9: 1023–1026
   PubMed Web of Science ®Google Scholar
• Montser E., Bosch F., Roman C. Treatment of B-cell chronic lymphocytic leukaemia current status and future perspectives. J Intern Med Suppl. 1997; 740: 63–67
   PubMedGoogle Scholar
• Tefferi A., Phyliky R. L. A clinical update on chronic lymphocytic leukemia. II. Critical analysis of current chemo-therapeutic modalities. Mayo Clin Proc 1992; 67: 457–461
   PubMed Web of Science ®Google Scholar
• Michallet M., Corront R., Hollard D., Gratwohl A., Domingo A., Burnett S. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: repot from the European Cooperative Group for bone marrow transplantation (8 cases). Nouv-Rev Fr Hematol 1988; 30: 467–470
   PubMedGoogle Scholar
• Khouri I. F., Keating M. J., Vriesendorp H. M., Reading C. L., Przepiorka D., Hah Y. O., Andersson B. S., van Besien K. W., Mehra R. C., Giralt S. A., et al. Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results. J Clin Oncol. 1994; 12: 748–758
   PubMed Web of Science ®Google Scholar
• Pavletic Z. S., Arrowsmith E. R., Goodman P. J., Vose S. A., Bierman J. M., Tarantolo S. R., Stein R. S., Bociek G., Greer J. P., Wu C. D., Kollath J. P., Weisenburger D. D., Kessinger A., Wolff S. N., Armitage J. O., Bishop M. R. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplantation 2000; 25: 717–722
   PubMed Web of Science ®Google Scholar
• Flinn I. W., Vogelsang G. Bone marrow transplantation for chronic lymphocytic leukemia. Semin Oncol 1998; 25: 60–64
   PubMed Web of Science ®Google Scholar
• Bandini G., Michallet M., Rosti G., Tura S. Bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 1991; 7: 251–253
   PubMed Web of Science ®Google Scholar
• Buhmann R., Nolte A., Westhaus D., Emmerich B., Hallek M. CD40-Activated B-Cell Chronic Lymphocytic Leukemia Cells fro Tumor Immunotherapy: Stimulation of Allogeneic Versus Autologous T Cells Generates Different Types of Effector Cells. Blood 1999; 93: 1992–2002
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Mohamed A. N., Hamdan M. Y., Vo T., Chen B., Katato K., Abubakr Y. A., Dugan M. C., al-Katib A. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model. Leukemia 1996; 10: 130–137
   PubMed Web of Science ®Google Scholar
• Mohammad R. M., Katato K., Almatchy V. P., Wall N., Liu K. Z., Schultz C. D., Mantsch H. H., Varterasian M., al-Katib A. M. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies. Clinical Cancer Research 1998; 4(2)445–453
   PubMed Web of Science ®Google Scholar
• Verbik D. J., Jackson J. D., Pirrucello S. J., Patil K. D., Kessinger A., Joshi S. S. Functional and phenotypic characterization of human peripheral blood stem cell harvests: A comparative analysis from consecutive collections. Blood 1985; 85: 1964–1970
   Google Scholar
• Rao A. K., Kuszynski C. A., Benner E., Iverson P. L., Jackson J. D., Bishop M. R., Joshi S. S. Increased growth inhibition of human chronic myelogenous leukemic cells by a combination of c-myb antisense oligonucleotide and 4-hydroxyperoxycyclophosphamide in vitro. International Journal of Oncology 1997; 11: 281–287
   PubMed Web of Science ®Google Scholar
• Pepper C., Thomas A., Hoy T., Cotter F., Bentley P. Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukeamia. British Journal of Haematology 1999; 107: 611–615
   PubMed Web of Science ®Google Scholar
• Kubin M. Z., Parshley D. L., Din W., Waugh J. Y., Davis-Smith T., Smith C. A., Macduff B. M., Armitage R. J., Chin W., Cassiano L., Borger L., Petersen M., Trinchieri G., Goodwin R. G. Molecular cloning and biological characterization of NK cell activation-inducing ligand, a counterstructure for CD48. European Journal of Immunology 1999; 29: 3466–3477
   PubMed Web of Science ®Google Scholar
• Foa R., Fierro M. T., Raspadori D., Bonferroni M., Cardona S., Guarini A., Tos A. G., di Celle P. F., Cesano A., Materd L. Lymphokine-Activated Killer (LAK) Cell Activity in B and T Chronic Lymphoid Leukemia: Defective LAK Generation and Reduced Susceptibility of the Leukemic Cells to Allogeneic and Autologous LAK Effectors. Blood 1990; 76: 1349–1354
   PubMed Web of Science ®Google Scholar
• Platsoucas C. D., Femandes G., Gupta S. L., Kempin S., Clarkson B., Good R. A., Gupta S. Defective spontaneous and antibody-dependent cytotoxicity mediated by E-rosette-positive and E-rosette-negative cells in untreated patients with chronic lymphocytic leukemia: augmentation by in vitro treatment with interferon. Journal of Immunology 1980; 125: 1216–1223
   PubMed Web of Science ®Google Scholar
• Foa R., Lauria F., Lusso P., Giubellino M. C., Fierro M. T., Ferrando M. L., Raspadori D., Materd L. Discrepancy between phenotypic and functional features of natural killer T-lymphocytes in B-cell chronic lymphocytic leukaemia. British Journal of Haemalology 1984; 58: 509–516
   PubMed Web of Science ®Google Scholar
• Lee R. K., Spielman J., Podack E. R. Bcl-2 protects against Fas-based but not perforin-based T cell-mediated cytolysis. Int Immunol 1996; 8: 991–100
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F., Gottardi D., Alfarano A., Stacchini A., Gregoretti M. G., Ghia P., Bertero M. T., Novarino A., Bergui L. The nature of the B lymphocyte in B-chronic lymphocytic leukemia. Blood Cells 1993; 19: 601–613
   PubMedGoogle Scholar
• Nagata S. Apoptosis mediated by the Fas system. Prog Mol Subcell Biol 1996; 16: 87–103
   PubMedGoogle Scholar
• Oshimi Y., Oda S., Honda Y., Nagata S., Miyazaki S. Involvement of Fas ligand and Fas-mediated pathway in the cytotoxicity of human natural killer cells. Journal of Immunology 1996; 157: 2909–2915
   PubMed Web of Science ®Google Scholar
• Medvedev A. E., Johnsen A. C., Haux J., Steinkjer B., Egeberg K., Lynch D. H., Sundan A., Espevik T. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine 1997; 9: 394–404
   PubMed Web of Science ®Google Scholar
• Bradley M., Zeytun A., Rafi-Janajreh A., Nagarkatti P. S., Nagarkatti M. Role of Spontaneous and Interleukin 2-Induced Natural Killer Cell Activity in the Cytotoxicity and Rejection of Fas+ and Fas- Tumor Cells. Blood 1998; 92: 4248–4255
   PubMed Web of Science ®Google Scholar